Biotechnology The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech Amgen and Japan’s Kyowa Kirin, with Phase III results for their rocatinlimab as a potential treatment for severe atopic dermatitis. In other news, Denmark’s Novo Nordisk released new data for its obesity hopeful CagriSema, which again failed to impress. Last week also saw US biotech 2seventy bio accept a takeover bid from Bristol Myers Squibb along with their partnered CAR-T cell therapy Abecma. Additionally, USA-based Sareum Holdings has in-licensed a cancer candidate, SRA737, from an unnamed company. 16 March 2025